Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Own stem cells may shield bone marrow during ovarian cancer chemo

NCT ID NCT05401162

Disease control Sponsor: Chongqing University Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This trial investigates whether giving back a patient's own blood stem cells after chemotherapy can help their bone marrow recover faster. The study includes women aged 18–60 with recurrent or metastatic ovarian cancer who are scheduled for chemotherapy. The goal is to reduce severe low white blood cell counts and other blood-related side effects, making treatment safer and more manageable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
autologous haematopoietic stem cells
What this could lead to
If it works, this approach could make chemotherapy safer and more tolerable for ovarian cancer patients by speeding up blood cell recovery.
What could go wrong
This is a small, early-stage study with 40 participants, so results may not apply to all patients. Risks include infection, bleeding, or stem cell transfusion reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2022

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18-60 years old; * there are chemotherapy indicators for ovarian cancer; * ovarian cancer diagnosed by histopathology; * recurrent and metastatic ovarian cancer; * the Eastern Cooperative Oncology Group (ECOG) performance status score≤1; * the expected survival time was more than 3 months; * pre-menopausal women (post-menopausal women must have been postmenopausal for at least 12 months to be considered infertile), and the serum pregnancy test results are negative; * all patients must agree to take effective contraceptive measures during the study period and within 6 months after stopping treatment; * the subjects voluntarily participate in this clinical trial sign an informed consent form and are able to complete the study procedures and follow-up examinations; * bone marrow function is good,ability to perform stem cell mobilisation and collection. Exclusion Criteria: * patients with bone marrow disease; * central nervous system or soft meningeal or bone or bone marrow metastases confirmed by imaging or pathology; * patient has severe cardiac insufficiency; * previous history of allogeneic stem cell transplantation or organ transplantation; * patients with active bleeding and autoimmune thrombocytopenic purpura; * patients with chemotherapy contraindications; * positive for human immunodeficiency virus (HIV); * acute or chronic active hepatitis B or hepatitis C infection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chongqing University Cancer Hospital

    RECRUITING

    Chongqing, Chongqing Municipality, 400030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.